Fluorouracil disrupts malignant cell viability through a defined molecular mechanism targeting tumour cell replication or survival dependencies. Its anticancer activity is characterised by MIC-equivalent IC50 values against tumour cell lines, in vivo antitumour efficacy in relevant xenograft models, and a clinical dose-response relationship linking plasma AUC to tumour response. The mutagenic and clastogenic potential of Fluorouracil demonstrated in standard genotoxicity studies necessitates linear extrapolation-based limit setting under ICH M7 for impurity assessment and pharmacologically-based OEL derivation for occupational exposure assessment.
Route-specific PDE values for Fluorouracil reflect systemic bioavailability differences between oral, parenteral, and inhalation administration. The parenteral PDE equals the oral PDE divided by oral bioavailability, since systemic exposure from an IV-contaminated product bypasses first-pass hepatic metabolism and gut-wall elimination.
